Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2335615 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL8966804 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL18975256 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL135863 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23014949 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL128978 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23014965 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL130671 | 1.00 | — | — | |
| SCHEMBL8907249 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL131692 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220362151-A1 | LIPOSOME FORMULATION | ROSI CHARNI AS (NO) | 2022-11-17 | — | — | US | disclosed |
| US-20220249525-A1 | Fatty Acid Compounds for Prevention and Treatment of Neurodegenerative Disorders | T OMEGA AS (NO) | 2022-08-11 | — | — | US | disclosed |
| EP-3982948-A1 | LIPOSOME FORMULATION | Rosi Charni AS (NO) | 2022-04-20 | — | — | EP | disclosed |
| EP-3972693-A1 | FATTY ACID COMPOUNDS FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS | T Omega AS (NO) | 2022-03-30 | — | — | EP | disclosed |
| WO-2020251368-A1 | LIPOSOME FORMULATION | ROSI CHARNI AS (NO) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020236010-A1 | FATTY ACID COMPOUNDS FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS | T OMEGA AS (NO) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236009-A1 | FATTY ACID COMPOUNDS FOR PREVENTION AND TREATMENT OF MITOCHONDRIAL DYSFUNCTION | T OMEGA AS (NO) | 2020-11-26 | — | — | WO | disclosed |
| EP-3687506-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| WO-2019195720-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| US-9029069-B2 | Resist underlayer film-forming composition and method for forming pattern | JSR CORPORATION (JP) | 2015-05-12 | — | — | US | disclosed |
| EP-1555018-A1 | REMEDIES FOR NEURODEGENERATIVE DISEASES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1535609-A1 | NF-KB ACTIVATION INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1535610-A1 | THERAPEUTIC AGENT FOR CANCER | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512397-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220249525-A1 | Fatty Acid Compounds for Prevention and Treatment of Neurodegenerative Disorders | FABP7, PSEN2, ELOVL1 | HSD17B10 259/4885MAPT 25/4885CYP1A2 4065/4885 |
| US-20220362151-A1 | LIPOSOME FORMULATION | LIPA, NPC1L1, LCAT | HSD17B10 438/4885MAPT 2392/4885CYP1A2 1575/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | HSD17B10 704/4885MAPT 2435/4885CYP1A2 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.